OncoQuest Receives 'Notice of Allowance' for Patent Protection of the Administration Schedule of Oregovomab and Chemotherapy for Stage III-IV Ovarian Cancer Patients

Source :: Women's Health Weekly. October 10, 2019, 112
Publication Year :: 2019
Abstract: 2019 OCT 10 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- OncoQuest Inc., a privately held, cancer immunotherapy company announced that a Notice of Allowance [...]

Subjects :: Oregovomab
Women's health
Cancer prevention
Chemotherapy
Carboplatin -- Intellectual property
Cancer patients
Biological products -- Intellectual property
Ovarian cancer
Patent law
Medical supplies
Cancer treatment
Trademarks
Antibodies
Immunotherapy
Editors
Health
Women's issues/gender studies

Tools